



ORIGINAL ARTICLE

## Characterization of acute heart failure hospitalizations in a Portuguese cardiology department

Ana Catarina Pinho-Gomes<sup>a</sup>, José Silva Cardoso<sup>a,b,c,\*</sup>, Luís Filipe Azevedo<sup>b</sup>, Rui Almeida<sup>c</sup>, Teresa Pinho<sup>c</sup>, Maria Júlia Maciel<sup>c</sup>

<sup>a</sup> Department of Cardiology, Faculty of Medicine, University of Porto, Porto, Portugal

<sup>b</sup> Department of Health Information and Decision Sciences (CIDES) and Centre for Research in Health Technologies and Information Systems (CINTESIS), Faculty of Medicine, University of Porto, Porto, Portugal

<sup>c</sup> Department of Cardiology, Hospital de S. João, Porto, Portugal

Received 8 September 2012; accepted 31 October 2012

Available online 16 July 2013

### KEYWORDS

Acute heart failure;  
Acute coronary syndrome;  
Management;  
Prognosis;  
Length of stay;  
Re-hospitalization;  
Mortality

### Abstract

**Introduction and Aims:** We describe the clinical characteristics, management and outcomes of patients hospitalized with acute heart failure in a south-west European cardiology department. We sought to identify the determinants of length of stay and heart failure rehospitalization or death during a 12-month follow-up period.

**Methods and Results:** This was a retrospective cohort study including all patients admitted during 2010 with a primary or secondary diagnosis of acute heart failure. Death and readmission were followed through 2011.

Of the 924 patients admitted, 201 (21%) had acute heart failure, 107 (53%) of whom had new-onset acute heart failure. The main precipitating factors were acute coronary syndrome (63%) and arrhythmia (14%). The most frequent clinical presentations were heart failure after acute coronary syndrome (63%), chronic decompensated heart failure (47%) and acute pulmonary edema (21%). On admission 73% had left ventricular ejection fraction <50%. Median length of stay was 11 days and in-hospital mortality was 5.5%. The rehospitalization rate was 21% and 24% at six and 12 months, respectively. All-cause mortality was 16% at 12 months. The independent predictors of rehospitalization or death were heart failure hospitalization during the previous year (Hazard ratio – HR – 3.177), serum sodium <135 mmol/l on admission (HR 1.995) and atrial fibrillation (HR 1.791). Reduced left ventricular ejection fraction was associated with a lower risk of rehospitalization or death (HR 0.518).

**Conclusions:** Our patients more often presented new-onset acute heart failure, due to an acute coronary syndrome, with reduced left ventricular ejection fraction. Several predictive factors of death or rehospitalization were identified that may help to select high-risk patients to be followed in a heart failure management program after discharge.

© 2012 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L. All rights reserved.

\* Corresponding author.

E-mail address: [silvacardoso30@gmail.com](mailto:silvacardoso30@gmail.com) (J. Silva Cardoso).

**PALAVRAS-CHAVE**

Insuficiência cardíaca aguda;  
 Síndrome coronária aguda;  
 Tratamento;  
 Prognóstico;  
 Duração de internamento;  
 Rehospitalização;  
 Mortalidade

**Caracterização das hospitalizações por insuficiência cardíaca aguda num serviço de cardiologia português****Resumo**

*Introdução e objetivos:* Dada a escassa informação relativa aos internamentos por insuficiência cardíaca aguda em serviços de Cardiologia portugueses, procedemos à sua caracterização. Pretendemos identificar os determinantes de maior duração de internamento e de rehospitalização ou morte aos 12 meses.

*Métodos e resultados:* Realizámos um estudo de cohort retrospectivo, incluindo os doentes admitidos em 2010 com diagnóstico primário ou secundário de insuficiência cardíaca aguda. A ocorrência de morte ou rehospitalização foi acompanhada durante 2011.

Do total de 924 hospitalizações, 201 (21%) apresentavam insuficiência cardíaca aguda, sendo o primeiro episódio em 107 (53%) das mesmas. Os principais fatores precipitantes foram síndrome coronária aguda (63%) e arritmia (14%). As apresentações clínicas mais comuns foram insuficiência cardíaca no contexto de síndrome coronária aguda (63%), insuficiência cardíaca crónica descompensada (46%) e edema pulmonar agudo (21%). Na admissão, 73% tinham fração de ejeção ventricular esquerda < 0,50. A duração mediana de internamento foi 11 dias e a mortalidade intra-hospitalar foi 5,5%. A taxa de rehospitalização aos 6 e 12 meses foi 21% e 24%, respetivamente. A mortalidade por todas as causas, aos 12 meses, foi 16%. Os fatores preditores de rehospitalização ou morte foram hospitalização por insuficiência cardíaca aguda no ano anterior (*Hazard ratio* – HR – 3,177), sódio sérico < 135 mEq/L na admissão (HR 1,995), fibrilhação auricular (HR 1,791). Fração de ejeção ventricular esquerda deprimida na admissão associou-se a menor risco de rehospitalização ou morte (HR 0,518).

*Conclusões:* Os nossos doentes apresentavam mais frequentemente insuficiência cardíaca aguda de novo, com fração de ejeção ventricular esquerda deprimida, no contexto de síndrome coronária aguda. Os vários fatores preditores de mortalidade ou rehospitalização identificados poderão contribuir para selecionar os doentes de alto risco que justificam acompanhamento especializado numa clínica de insuficiência cardíaca.

© 2012 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L. Todos os direitos reservados.

**Introduction**

Acute heart failure (AHF) is a major public health concern because of its increasing prevalence and associated high morbidity, mortality and costs.<sup>1-5</sup> Despite being one of the most frequent reasons for hospitalization in western countries, it has received much less attention than chronic heart failure (CHF), and large-scale studies specifically addressing AHF are relatively scarce.<sup>6,7</sup>

AHF is associated with a high rate of rehospitalization but little is known regarding the most relevant predictive factors. It is therefore important to develop appropriate predictive models that might help to appropriately stratify AHF patients and improve their management and follow-up.<sup>8</sup>

Moreover, although several studies have been conducted in Europe and the USA on the clinical characteristics, treatment and outcome of AHF patients, little information is available on this subject in Portugal.<sup>9</sup>

In the present study we describe the clinical characteristics, hospital management and outcomes of AHF patients admitted to a Portuguese cardiology department, and present a predictive model for readmission or death at 12 months in this population.

**Objectives**

The primary objective of this study was to describe the clinical characteristics, hospital management and outcomes of patients hospitalized with AHF.

The secondary objectives were:

- to compare patients with AHF and acute coronary syndrome (ACS) as the precipitating factor vs. patients with AHF and no ACS;
- to compare drug prescriptions on admission and at discharge;
- to identify factors associated with longer hospital length of stay (LOS);
- to identify risk factors for heart failure (HF) rehospitalization or death.

**Methods****Study description**

This was a hospital-based observational retrospective cohort study, conducted at the Cardiology Department of Hospital de S. João, Porto, Portugal. Demographic, clinical and follow-up data were collected between February 1, 2011 and December 31, 2011, ensuring a minimum follow-up of one year for all patients.

**Inclusion criteria**

All patients admitted to the cardiology department between January 1 and December 31, 2010 were screened. Paper-based and computerized clinical records on the 924 patients

**List of abbreviations**

ACEI	angiotensin-converting enzyme inhibitor
ACS	acute coronary syndrome
AF	atrial fibrillation
AHF	acute heart failure
ARB	angiotensin receptor blocker
BB	beta-blocker
BNP	B-type natriuretic peptide
CCB	calcium channel blocker
CDHF	chronic decompensated heart failure
CHD	coronary heart disease
CHF	chronic heart failure
CI	confidence interval
DBP	diastolic blood pressure
ECG	electrocardiogram
ESC	European Society of Cardiology
HF	heart failure
HR	hazard ratio
ICCU	intensive cardiac care unit
ICD	implantable cardioverter-defibrillator
LAD	left atrial diameter
LOS	length of stay
LVED	left ventricular end-diastolic diameter
LVEF	left ventricular ejection fraction
MRA	mineralocorticoid receptor antagonist
SBP	systolic blood pressure
SD	standard deviation
VT	ventricular tachyarrhythmia

admitted during the study period were retrieved and analyzed by one investigator in order to find eligible patients who met one of the following inclusion criteria:

- Primary diagnosis of AHF according to ESC criteria<sup>3</sup>;
- AHF secondary to another acute cardiac event<sup>3</sup>;
- Acute myocardial infarction classified as Killip II–IV.

**Exclusion criteria**

Scheduled hospitalizations or hospitalizations in the context of cardiac surgery were considered exclusion criteria.

In order to avoid duplicate records, readmissions to the hospital during the study period were not counted as new cases.

**Data collection**

Data on patient demographics, cardiovascular risk factors, comorbidities and history of cardiac disease or HF, and results of ECG, hemodynamic, echocardiographic examinations and laboratory tests were collected, as well as on the etiology and the possible precipitating factors of AHF, drug prescriptions before and following admission, concomitant medication and the main diagnostic or therapeutic procedures performed during hospitalization. The hospital LOS of patients was also recorded; in cases of patients transferred

to another hospital or to another ward, it was recorded at the time of transfer. Data regarding death or rehospitalization were obtained from the patient's electronic record and did not include admissions to another hospital or death not recorded in the hospital's administrative or clinical database. For all living patients, the follow-up period ended on December 31, 2011.

**Data analysis**

Categorical variables were presented as counts and percentages, and quantitative variables as means and standard deviation (SD) or medians and 25th percentile–75th percentile (p25–p75) as appropriate, depending on the empirical distribution of the variables.

Subgroups of patients were compared using the chi-square test or Fisher's exact test for categorical variables and the t test and Mann–Whitney rank-sum test for symmetrical and asymmetrical quantitative variables, respectively. The normality of the distribution of quantitative variables was assessed by the Kolmogorov–Smirnov test.

Simple and multiple linear regression models were used to analyze the variable LOS, which was logarithmically transformed in order to normalize its initially asymmetrical distribution. Survival analysis was used to analyze determinants of rehospitalization or death. For graphs of survival probability, the crude effect of each variable was tested with the log-rank test and multivariate analysis was performed using the Cox regression model. In the final analysis, all variables were taken into account to obtain a fully adjusted model. For each variable the assumption of proportional hazards was tested.

In univariate and multivariate regression analysis, the dependent variables were LOS and an adverse event, defined as HF rehospitalization or death during the follow-up period. The independent variables were age, gender, ischemic etiology, type (new-onset vs. decompensated chronic HF), history of HF hospitalization in the previous 12 months, obesity, diabetes, intensive cardiac care unit (ICCU) admission, LOS and the following admission findings: systolic blood pressure <100 mmHg, heart rate <70 bpm, serum sodium <135 mmol/l, serum potassium >4.3 mmol/l, creatinine clearance <30 ml/min, anemia (hemoglobin lower than 130 g/l in men and 120 g/dl in women), serum B-type natriuretic peptide (BNP) >500 pg/ml, atrial fibrillation (AF), and left ventricular ejection fraction (LVEF) <50%. In the independent variables, the variable etiology was included instead of ACS as precipitating factor, since there was a close association between the two variables but etiology was considered more informative.

All tests were two-sided and p values less than 0.05 were considered as indicating significant differences. The analysis was performed using SPSS 18.0 for Windows statistical software.

**Ethics**

The study was carried out according to the principles of the Declaration of Helsinki and was approved by the hospital's ethics committee.

**Table 1** Underlying diseases, type of onset, precipitating factors and clinical presentation of acute heart failure patients.

	All patients (n=201)	Patients with ACS (n=127)	Patients without ACS (n=74)	p
<i>Number (%)</i>	201	127 (63.2)	74 (36.8)	
<i>Age, mean (SD)</i>	69 (13)	71 (11)	66 (14)	0.018
<i>Male (%)</i>	60.7	55.1	70.3	0.034
<i>Body mass index (kg/m<sup>2</sup>), mean (SD)</i>	26 (4)	26 (4)	26 (4)	0.459
<i>Cardiovascular disease (%)</i>				
Chronic hypertension	66.2	72.4	55.4	0.014
Coronary artery disease	38.3	44.9	27.0	0.012
Valvular disease	14.9	5.5	31.1	<0.001
Dilated cardiomyopathy	7.5	1.6	17.6	<0.001
<i>Comorbidities (%)</i>				
Diabetes	37.8	37.0	39.2	0.758
Obesity	31.3	22.8	45.9	0.001
Dyslipidemia	51.2	54.3	45.9	0.251
Smoking	35.3	37.8	31.1	0.337
Chronic pulmonary disease	12.4	10.2	16.2	0.215
Chronic kidney disease	19.4	15.0	27.0	0.037
Anemia	35.8	33.1	40.5	0.287
Active cancer	3.0	3.1	2.7	1.000
Psychiatric disorder	6.5	8.7	2.7	0.098
Alcohol abuse	8.5	9.4	6.8	0.508
<i>Pacemaker implanted (%)</i>	3.5	1.6	6.8	0.103
<i>ICD (%)</i>	3.5	0.0	9.5	0.001
<i>HF hospitalization within last 12 months (%)</i>	14.9	8.7	25.7	0.001
<i>New-onset AHF (%)</i>	53.2	74.0	17.6	<0.001
<i>Precipitating factors on admission (%)</i>				
ACS	63.2	127	0	
Arrhythmia	14.4	0	39.2	
Drug or dietary noncompliance	8.0	0	21.6	
Valve disease	7.0	0	18.9	
Infection	6.0	0	16.2	
<i>Clinical presentation (%)</i>				
CDHF	46.8	26.0	82.4	<0.001
Pulmonary edema	21.4	26.0	13.5	0.038
Hypertensive HF	0.5	0.0	1.4	0.368
Cardiogenic shock	6.0	8.7	1.4	0.035
Isolated right HF	0.5	0.0	1.4	0.059
HF in the context of ACS	63.2	100.0	0.0	<0.001

p value for difference between patients presenting with or without ACS. Anemia defined as serum hemoglobin on admission <130 g/l for men and 120 g/l for women; all other comorbidities as reported. ACS: acute coronary syndrome; AHF: acute heart failure; CDHF: chronic decompensated heart failure; HF: heart failure; ICD: implantable cardioverter/defibrillator; SD: standard deviation.

## Results

### Baseline characteristics

Of a total of 924 patients admitted to the cardiology department over a period of one year, 201 (21%) presenting with AHF were enrolled. Patients' baseline characteristics are summarized in [Tables 1 and 2](#). New-onset AHF occurred in more than 50% of cases. Hypertension and coronary heart disease (CHD) were the most prevalent underlying diseases, but all the cardiovascular risk factors were relatively frequent. The most common precipitating factor was ACS (63.3% of patients), followed by arrhythmia (14.4%

of patients). The most frequent clinical presentation by far was HF in the context of ACS, followed by chronic decompensated heart failure (CDHF) and pulmonary edema. Interestingly, pulmonary edema was approximately twice as common in patients presenting with ACS than in those with no ACS, while CDHF was approximately three times more frequent in those without ACS than in those with. The majority of patients had reduced LVEF on admission.

Patients presenting with ACS were significantly younger, more often women and less likely to have a history of HF; they more often had chronic hypertension and CHD. On the other hand, patients without ACS more frequently had valvular disease and dilated cardiomyopathy, left

**Table 2** Physical, laboratory, electrocardiographic and echocardiographic findings on admission.

	All patients (n=201)	Patients with ACS (n=127)	Patients without ACS (n=74)	p
<b>Physical findings, mean (SD)</b>				
SBP (mmHg)	128 (31)	130 (31)	125 (31)	0.350
DBP (mmHg)	74 (20)	75 (20)	72 (19)	0.191
Heart rate (bpm)	88 (31)	87 (28)	89 (35)	0.705
Oxygen saturation (%), median [p25–p75]	96 [91–98]	95 [90–98]	96 [93–98]	0.220
<b>Laboratory values, mean (SD) or median [p25–p75]</b>				
Serum hemoglobin (g/l)	126 [110–139]	125 [111–141]	128 [106–139]	0.732
BNP (pg/ml)	841 [313–1804]	765 [266–1463]	1001 [377–2325]	0.111
Creatinine clearance (ml/min)	57.5 (21.4)	59.3 (21.1)	54.3 (21.7)	0.105
<30 ml/min (%)	10.0	8.7	12.2	0.482
Serum sodium (mmol/l)	138 [135–140]	137 [130–140]	138 [136–140]	0.300
Serum potassium (mmol/l)	4.1 [3.9–4.5]	4.0 [3.7–4.5]	4.3 [4.0–4.6]	0.025
<b>ECG (%)</b>				
Atrial fibrillation	30.8	22.0	45.9	<0.001
VT	10.4	7.1	16.2	0.041
Myocardial infarction	66.7	91.3	24.3	<0.001
L VH	8.5	4.7	14.9	0.013
<b>Echocardiography</b>				
LVEF (%)				
Preserved	26.8	22.4	34.8	
Moderately reduced	37.1	44.8	23.2	0.010
Severely reduced	36.1	32.8	42.0	
LA diameter (mm), median [p25–p75]	43 [40–48]	42 [39–45]	47 [43–55]	<0.001
LVED diameter (mm), median [p25–p75]	52 [48–59]	51 [47–55]	58 [50–64]	<0.001

p value for difference between patients presenting with or without ACS. DBP: diastolic blood pressure; LA: left atrial; LVED: left ventricular end-diastolic; LVEF: left ventricular ejection fraction; LVH: left ventricular hypertrophy; SBP: systolic blood pressure; SD: standard deviation; VT: ventricular tachyarrhythmia.

ventricular hypertrophy pattern on the ECG, larger left atrial diameter and AF.

### Hospital course and management

Echocardiographic examination and BNP measurement were performed in most patients and the majority were admitted to the ICCU and underwent coronary angiography. Overall use of in-hospital resources was similar in both ACS and non-ACS groups (Table 3), although a higher proportion of ACS patients were admitted to the ICCU. Non-invasive ventilation, intravenous nitrates and diuretics were the basis of therapy and the first two were more often used in ACS patients.

### Discharge characteristics

Comparing admission with discharge, we observed a significant drop in body weight (median  $-3$  kg [p25–p75:  $-6$ – $0$ ];  $p<0.001$ ), systolic blood pressure (mean  $-17.1$  mmHg; SD 29.7;  $p<0.001$ ), heart rate (mean  $-18.7$  bpm; SD 32.4;  $p<0.001$ ) and BNP (median  $-203.5$  pg/dl [p25–p75:  $-850.5$ – $74.9$ ];  $p<0.001$ ). There was no improvement in creatinine clearance, serum sodium and potassium, or serum hemoglobin. The rate of prescription of all cardiovascular

drugs increased from admission to discharge, apart from digoxin and calcium channel blockers (Figure 1).

### Hospital stay and follow-up

Total LOS was similar in the two groups (median 11 days). In-hospital mortality was 5.5% and was not significantly different between the two groups. The rate of rehospitalization for HF was 20.9% and 23.9% at six and 12 months, respectively. Most readmissions occurred within six weeks after the index event. All-cause mortality was 10.9% and 15.9% at six and 12 months, respectively. The variables independently associated with a longer LOS were history of HF hospitalization in the previous year ( $p=0.040$ ), BNP  $>500$  pg/ml ( $p<0.001$ ) on admission and ICCU admission ( $p=0.002$ ) (Table 1S in Supplementary Material).

The most important variables predictive of the combined endpoint of rehospitalization or death during follow-up were history of HF hospitalization in the previous year (hazard ratio [HR] 3.177 [1.405–7.185]), serum sodium  $<135$  mmol/l on admission (HR 1.995 [1.032–3.856]) and AF (HR 1.791 [1.021–3.142]). Reduced LVEF (HR 0.518 [0.268–0.998]) was associated with a lower risk of rehospitalization or death (Table 2S in Supplementary Material).



**Table 3** Diagnostic investigations, procedures and acute cardiac care.

Procedure/treatment (% performed)	All patients (n=201)	Patients with ACS (n=127)	Patients without ACS (n=74)	p
Admission to ICCU	77.1	91.3	52.7	<0.001
ECG	98.5	100.0	95.9	0.049
Echocardiography	96.5	98.4	93.2	0.103
BNP	89.6	91.3	86.5	0.340
Cardiac scintigraphy	10.4	13.4	5.4	0.074
Coronary angiography	69.7	85.3	45.9	<0.001
Pulmonary artery catheter	5.5	4.7	6.8	0.188
Percutaneous coronary intervention	32.8	48.8	5.4	<0.001
Invasive ventilation	8.5	8.7	8.1	0.892
Non-invasive ventilation	63.5	69.3	53.4	0.025
Intravenous diuretics	62.5	58.3	59.9	0.103
Intravenous nitrates	34.5	42.5	20.5	0.002
Intravenous inotropes	13.9	13.4	14.9	0.770
Intra-aortic balloon pump	3.5	5.5	0.0	0.048
Dialysis	2.5	2.4	2.7	1.000
Pacemaker	5.0	1.6	10.8	0.004
ICD	6.5	4.7	9.5	0.188

p value for difference between patients presenting with or without ACS. ACS, acute coronary syndrome; BNP, B-type natriuretic peptide; ICCU, intensive cardiac care unit; ICD, implantable cardioverter/defibrillator.

## Discussion


Hospitalizations due to AHF are associated with high mortality and readmission rates, and represent about 70% of all costs associated with HF.<sup>10,11</sup> They typically occur in internal medicine or cardiology departments and thus most studies include a mixed population from both provenances.

Clinical information provided by hospital-based studies is crucial to our understanding of the contemporary clinical characteristics of AHF, including key prognostic factors and details regarding clinical presentation and medical therapy. We therefore conducted a hospital-based observational retrospective study in order to identify the particular

characteristics of AHF patients admitted exclusively to a cardiology department.

### Demographics, underlying diseases, type of onset, precipitating factors and clinical presentation of acute heart failure

In our study, the mean age and gender distribution of patients were similar to those of previous AHF registries in Europe and elsewhere<sup>7,12</sup> and in the USA.<sup>13</sup> However, our patients were younger and more often male than those included in an earlier Portuguese study performed in



**Figure 1** Oral medication on admission and at discharge for acute heart failure patients. McNemar test for related samples. ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; BB: beta-adrenergic receptor blocker; CCB: calcium channel blocker; MRA: mineralocorticoid receptor antagonist.

internal medicine wards.<sup>9</sup> Unlike in many previous reports, the majority of our patients had reduced LV function, which was perhaps a consequence of the high prevalence of ACS in our population. Interestingly, a recent Italian study<sup>14</sup> also showed that patients admitted to cardiology departments were younger, more often male and more likely to have reduced LVEF than patients in internal medicine wards, which is in agreement with our findings but not with the aforementioned Portuguese study.<sup>9</sup>

Cardiovascular disease was common among our patients, most frequently CHD and hypertension, as observed in previous international surveys.<sup>7,12,13</sup> Conventional cardiovascular risk factors, such as obesity, diabetes and dyslipidemia, were also very frequent. The prevalence of noncardiovascular comorbidities was similar to that observed in previous surveys<sup>12,13</sup>. Chronic pulmonary diseases, anemia and kidney disease were common, with mean creatinine clearance compatible with grade 3 renal failure. This was similar to that observed in ADHERE,<sup>13</sup> highlighting the importance of heart-kidney interaction in AHF.

Most patients had new-onset HF, particularly those with an ACS as precipitating factor. The prevalence of new-onset AHF was much higher than in EHFSII<sup>12</sup> and ALARM-HF.<sup>7,13</sup>

ACS was the precipitating factor in nearly two-thirds of patients. This was almost twice the figure observed in reports<sup>7,12</sup> that included patients of mixed provenance (from internal medicine and cardiology departments). Arrhythmias were the second most frequent precipitating factor and were more common in the non-ACS group. They were mostly of supraventricular origin, which is in line with previous reports of the high frequency of AF among AHF patients.

As in EHFSII<sup>12</sup> and ALARM-HF,<sup>7</sup> two of the most common clinical presentations of AHF in our population were CDHF and pulmonary edema.

### Diagnostic investigations and treatment

ECG, BNP measurement and echocardiographic examination were performed in nearly all patients on admission or within the first days of hospitalization, showing good adherence to the European Society of Cardiology (ESC) HF guidelines.<sup>3</sup> The high prevalence of ACS explains why coronary angiography was performed in more than two-thirds of our patients and why a considerably higher percentage of them were admitted to the ICCU, compared to EHFSII.<sup>12</sup>

As previously reported by others,<sup>7,12,13</sup> ventilatory support and intravenous diuretic therapy played a central role in acute management. Non-invasive ventilation was used in the majority of patients. The frequency of administration of intravenous nitrates was similar to that in previous surveys,<sup>7,12,13</sup> while the use of inotropes was nearly half. Approximately one-third of the patients presented with ST-segment elevation myocardial infarction and underwent percutaneous coronary intervention. This was considerably more frequent than in ADHERE<sup>13</sup> and EHFSII.<sup>12</sup>

The observed decrease in body weight, heart rate and BNP at discharge reflected clinical improvement with therapy. Interestingly, blood pressure fell, but no improvement in serum creatinine value was observed, which demonstrates the limitations of current therapeutic options regarding renal function.

The prescription of drugs recommended for HF, CHD and hypertension increased significantly from admission to discharge. However, the proportion of patients taking angiotensin converting-enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) was lower than in EHFSII<sup>12</sup>; a possible explanation for this may be the proportion of our patients (26.8%) with HF and preserved LVEF, for which these drugs are not formally indicated. By contrast, the levels of prescription of beta-blockers, statins, aspirin, clopidogrel and nitrates at discharge exceeded that of EHFSII,<sup>12</sup> possibly because ACS was more frequent in our study than in that survey and these drugs are recommended for secondary prophylaxis of ACS.

### Length of stay, outcomes and follow-up of acute heart failure patients (Table 4)

The overall LOS was 11 days, two days longer than in EHFSII<sup>12</sup> and ALARM-HF<sup>7</sup> and almost three times that reported in ADHERE.<sup>13</sup> The median ICCU stay was six days, twice that reported in EHFSII<sup>12</sup> and ALARM-HF.<sup>7</sup> However, in our case, in-hospital mortality was 5.5%, which was lower than in EHFSII<sup>12</sup> (6.6%) and ALARM-HF<sup>7</sup> (12%). The large-scale US surveys ADHERE<sup>13</sup> and OPTIMIZE-HF<sup>15</sup> reported in-hospital mortality of nearly 4%, which is even lower than ours. Nonetheless, this low in-hospital mortality, which may in part have been a consequence of the very short LOS, was counterbalanced by higher readmission rate and long-term mortality (for instance, OPTIMIZE-HF<sup>15</sup> showed 90-day rehospitalization rates and mortality of 30% and 35%, respectively). It is possible that longer hospital stay could enable better patient stabilization, reducing long-term morbidity and mortality.

Our results reinforce the notion that AHF hospitalizations are associated with poor prognosis, with more than one-third of patients dying or being rehospitalized over the subsequent year.

Our patients with new-onset AHF had a more severe clinical presentation, which is consistent with ALARM-HF.<sup>7</sup> However, in the long run patients with CDHF had a higher risk of rehospitalization or death.

The probability of being rehospitalized was highest during the first weeks after discharge from the index event, which attests the need of an early medical appointment after discharge, preferably in the setting of a particular HF management program.<sup>3</sup>

### Predictive factors of longer hospitalization and adverse outcome

The predictive factors for rehospitalization after an AHF event are largely unexplored in the literature.<sup>16</sup> In our study a baseline BNP value higher than 500 pg/ml was the most important factor associated with longer LOS, followed by admission to the ICCU, both indicating a more severe initial clinical picture. History of HF hospitalizations in the previous year, a recognized marker of bad prognosis,<sup>3</sup> was also associated with longer hospital stay and with a threefold increase in the risk of dying or being rehospitalized during the year after discharge. AF also showed a significant

**Table 4** Length of stay, outcomes and follow-up.

	All patients (n=201)	Patients with ACS (n=127)	Patients without ACS (n=74)	p
<i>Length of stay (days), median [p25–p75]</i>				
Total	11 [7–16]	11 [7–16]	11 [6–18]	0.864
ICCU	6 [4;12]	3 [2;5]	1 [0;4]	<0.001
Cardiology ward	6 [4;12]	6 [4;11]	7 [4;14]	0.131
<i>In-hospital mortality (%)</i>	5.5	3.9	8.1	0.210
<i>Follow-up</i>				
Hospitalization within 6 months (%)	20.9	18.9	24.3	0.361
Hospitalization within 12 months (%)	23.9	22.8	25.7	0.649
<i>Department of first readmission (%)</i>				
Cardiology department	27.1	24.1	31.6	
Internal medicine department	66.7	69.0	63.2	0.843
ICU of emergency department	6.3	6.9	5.3	
<i>Months after index admission, median [p25–p75]</i>	1.5 [0.8–4.5]	2.0 [1.0–5.0]	1.5 [0.5–4.0]	0.586
<i>Rehospitalizations,<sup>a</sup> median [p25–p75]</i>	1 [1–2]	1 [1–2]	1 [1–2]	0.605
<i>Mortality at six months (%)</i>				
Heart failure	7.5	4.7	12.2	0.053
All-cause	10.9	8.7	14.9	0.174
<i>Mortality at 12 months (%)</i>				
Heart failure	10.9	8.7	14.9	0.174
All-cause	15.9	14.2	18.9	0.375
Adverse endpoint <sup>b</sup>	34.8	31.5	40.5	0.301

<sup>a</sup> Number of heart failure rehospitalizations during the year after index admission.

<sup>b</sup> Adverse endpoint defined as death or heart failure rehospitalization during the total follow-up period. p value for difference between patients presenting with or without ACS. ICCU: intensive cardiac care unit; ICU: intensive care unit.

association with increased risk of rehospitalization or death, which is in keeping with literature on CHF.<sup>3,17–21</sup>

Other variable also independently associated with a poor long-term outcome was serum sodium <135 mmol/l on admission, while reduced LVEF was associated with better prognosis. Together they can help to select high-risk patients for inclusion in specific HF clinic. This is important, since these management programs can reduce rehospitalizations and mortality, are cost-effective and in the ESC guidelines have class I recommendation, level of evidence A, for recently hospitalized HF patients.<sup>3</sup> However, in many countries, due to financial constraints and insufficient manpower, it is not possible to admit all hospitalized HF patients to an HF management program. Thus, identifying predictors of increased vulnerability can help to select patients most in need of these programs.

### Patients with vs. without acute coronary syndrome as the precipitating factor

Patients with an ACS typically presented left atrial dilatation, preserved left ventricular dimensions and reduced LVEF on admission. Left atrial dilatation was possibly a consequence of history of hypertension observed in more than 70% of patients. On the contrary, in the early days of new-onset AHF due to an ACS, the left ventricle would not have had sufficient time to undergo eccentric remodeling.

Patients with ACS had more frequent and longer ICCU admissions and were more often treated with non-invasive

ventilation and intra-aortic balloon pump than those without ACS. This suggests they have a worse initial clinical course. Nonetheless, there was no difference between groups in total hospital LOS, readmission rate, in-hospital mortality or mortality at six or 12 months.

### Study limitations

An inherent limitation of this study derives from its retrospective nature. An additional drawback is the possibility that death or rehospitalization occurring out of our institution during follow-up were not reported. This could partly explain the observed low long-term rehospitalization and death rates. However, the consistency in the referral of patients indicates that this was probably not a major problem, and moreover cannot explain the low rates of in-hospital mortality also found in our study.

### Conclusion

Patients admitted to our cardiology department with AHF more typically presented new-onset AHF, in the context of an ACS, causing deterioration in LV systolic function. They had longer LOS but lower 12-month readmission rate and mortality than reported in US and European studies. Independent predictors of rehospitalization or death were HF hospitalization during the previous year, serum sodium <135 mmol/l on admission and AF. Reduced LVEF was associated with a decreased risk of rehospitalization or death.



## Ethical disclosures

**Protection of human and animal subjects.** The authors declare that no experiments were performed on humans or animals for this study.

**Confidentiality of data.** The authors declare that they have followed the protocols of their work center on the publication of patient data and that all the patients included in the study received sufficient information and gave their written informed consent to participate in the study.

**Right to privacy and informed consent.** The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

## Conflicts of interest

The authors have no conflicts of interest to declare.

## Appendix A. Supplementary material

Supplementary material associated with this article can be found, in the online version, at [doi:10.1016/j.repc.2012.10.018](https://doi.org/10.1016/j.repc.2012.10.018).

## References

1. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, et al. Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. *Circ J*. 2006;70:1617–23.
2. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. *Circulation*. 2005;112:e154–235.
3. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur J Heart Fail*. 2008;10:933–89.
4. Jessup M, Brozena S. Heart failure. *N Engl J Med*. 2003;348:2007–18.
5. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. *JAMA*. 2006;296:2217–26.
6. Rudiger A, Harjola VP, Muller A, et al. Acute heart failure: clinical presentation, one-year mortality and prognostic factors. *Eur J Heart Fail*. 2005;7:662–70.
7. Follath F, Yilmaz MB, Delgado JF, et al. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). *Intensive Care Med*. 2011;37:619–26.
8. Betihavas V, Davidson PM, Newton PJ, et al. What are the factors in risk prediction models for rehospitalisation for adults with chronic heart failure? *Aust Crit Care*. 2012;25:31–40.
9. Sarmiento PM, Fonseca C, Marques F, et al. Acutely decompensated heart failure: characteristics of hospitalized patients and opportunities to improve their care. *Rev Port Cardiol*. 2006;25:13–27.
10. Biermann J, Neumann T, Angermann CE, et al. Economic burden of patients with various etiologies of chronic systolic heart failure analyzed by resource use and costs. *Int J Cardiol*. 2012.
11. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics – 2011 update: a report from the American Heart Association. *Circulation*. 2011;123:e18–209.
12. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. *Eur Heart J*. 2006;27:2725–36.
13. Adams Jr KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). *Am Heart J*. 2005;149:209–16.
14. Di Lenarda A, Scherillo M, Maggioni AP, et al. Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds – the TEMISTOCLE study. *Am Heart J*. 2003;146:E12.
15. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. *J Am Coll Cardiol*. 2007;50:768–77.
16. Zannad F, Adamopoulos C, Mebazaa A, et al. The challenge of acute decompensated heart failure. *Heart Fail Rev*. 2006;11:135–9.
17. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. *Studies of Left Ventricular Dysfunction*. *J Am Coll Cardiol*. 1998;32:695–703.
18. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. *N Engl J Med*. 1997;336:525–33.
19. Kober L, Swedberg K, McMurray JJ, et al. Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. *Eur J Heart Fail*. 2006;8:591–8.
20. Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. *J Am Coll Cardiol*. 2006;47:1997–2004.
21. Ahmed MI, White M, Ekundayo OJ, et al. A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study. *Eur Heart J*. 2009;30:2029–37.